Lung Biopsy Articles & Analysis
8 news found
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer detection and monitoring of lung ...
Key priorities in this development will be the completion of the clinical development programs that are already underway in liver and breast cancer and their regulatory approval, as well as thecompletion of the industrial scale-up in Europe and the US of the safe-biopsy device, which has already been clinically tested in lung and liver biopsy. ...
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening ...
August 1 marks World Lung Cancer Day -- a time to raise awareness of the need for increased lung cancer research and innovation. Anyone can get lung cancer. Here are the facts you need to know: Lung cancer is the leading cause of cancer deaths worldwide More patients die every year from lung cancer than from ...
Previous research has demonstrated that the LuCED lung test, a non-invasive liquid biopsy sputum assay, has potential to address critical unmet medical needs to advance the lung cancer interception and management in three areas: 1) accurate diagnosis of small and early stage tumors and pulmonary nodules; 2) detection and treatment of ...
The research presented was performed using cells that were within normal limits from patients with biopsy confirmed lung cancer and from donors who were cancer free. Cells from sputum were imaged by the Cell-CT platform which produced a set of morphometric biosignatures from each cell. ...
Our lead investigative pharmaceutical drug is oral iloprost, currently in clinical development for the treatment of pre-cancerous bronchial dysplasia and the prevention of lung cancer following a successful Phase 2 clinical trial. The LuCED® lung test will be the companion diagnostic for oral iloprost. VisionGate’s proprietary LuCED ...
Cancer Diagnostics Services: Our initial cancer diagnostic services test, the LuCED® lung test, has been developed to support the early detection of lung cancer. ...